Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system by Omedes Pujol M et al.
 Newcastle University ePrints 
 
Omedes Pujol M, Coleman DJL, Allen CD, Heidenreich O, Fulton 
DA. Determination of key structure-activity relationships in siRNA delivery 
with a mixed micelle system.  
Journal of Controlled Release 2013, 172(3), 939-945. 
 
Copyright: 
© 2013 The Authors. Published by Elsevier B.V. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
DOI link to article: 
http://dx.doi.org/10.1016/j.jconrel.2013.10.013 
Date deposited:  10th January 2014 
 
 
 
This work is licensed under a Creative Commons Attribution 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Journal of Controlled Release 172 (2013) 939–945
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lDetermination of key structure–activity relationships in siRNA delivery
with a mixed micelle system☆,☆☆Marta Omedes Pujol a, Daniel J.L. Coleman b, Christopher D. Allen b, Olaf Heidenreich b,⁎, David A. Fulton a,⁎⁎
a Chemical Nanoscience Laboratory, School of Chemistry, Newcastle University, Newcastle upon Tyne, UK
b Northern Institute of Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, UKAbbreviations: AML, acute myeloid leukaemia; PNP, p
b-PDMAEMA; P2, PCL-b-PEG; siRNA, short interfering r
FACS, fluorescent activated cell sorting; LSCM, laser scann
☆ This is an open-access article distributed under the t
Attribution License, which permits unrestricted use, dis
any medium, provided the original author and source are
☆☆ The manuscript was written through contributions
given approval to the final version of the manuscript. All
⁎ Correspondence to: O. Heidenreich, Northern Inst
O'Gorman Building, Newcastle University, Framlington P
4HH, UK. Tel.: +44 191 246 4365.
⁎⁎ Correspondence to: D.A. Fulton, Bedson Building, S
University, Newcastle upon Tyne NE1 7RU, UK. Tel.: +44
E-mail addresses: olaf.heidenreich@ncl.ac.uk (O. Heid
(D.A. Fulton).
0168-3659/$ – see front matter © 2013 The Authors. Pub
http://dx.doi.org/10.1016/j.jconrel.2013.10.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 26 July 2013
Accepted 9 October 2013
Available online 18 October 2013
Keywords:
siRNA
Polymer micelles
Leukaemia
Structure–activity relationships
Gene knockdownShort interfering ribonucleic acids (siRNAs) offer a highly specific and selective form of therapy for diseases with a
genetic component; however the poor pharmacokinetic properties of the molecule have impeded its development
into a therapeutic for use in vivo. Several different approaches havebeen taken todevelop a successful siRNAdelivery
systembut these systems lack the flexibility for easy optimisation. Here,we propose a polymeric nanoparticle (PNP)
system consisting of two amphiphilic diblock copolymers which allow for the rapid determination of structure–
activity relationships involving gene knockdown and toxicity. The diblock copolymers self-assemble into
monodisperse micelles of defined hydrodynamic diameters ranging from 30 to 100 nm dependent on the
copolymer ratio. A luciferase-based high throughput assay varying PNP composition, concentration and siRNA
concentration allowed the rapid identification of efficient PNP formulations for adherent and suspension cell
lines. Optimised PNPs efficiently knocked down a fusion oncogene in hard to transfect human leukaemic cells
raising the possibility of targetingmalignant cells in a cancer-specific fashion. This approach allows the optimum
PNP formulation to be identified for different cell types and conditions.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Small interfering RNAs (siRNAs) are short double stranded RNAs
which can silence the expression of specific genes by inducing cleavage
and subsequent degradation of messenger RNA [1–3]. siRNAs are a
very attractive tool to interrogate gene function and hold substantial
therapeutic promise, in particular with cancer-specific fusion genes,
which are unique to tumour cells and absolutely required for cancer
maintenance both in cell culture and in vivo [4]. Of particular interest
to us is RUNX1/ETO, a fusion gene found in Acute Myeloid Leukaemia
(AML) cells and which acts as a regulator of transcription without
intrinsic enzymatic activity, making it a difficult target for conventionalolymeric nanoparticle; P1, PCL-
ibonucleic acid; NR, Nile Red;
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[5,6].
The unfavourable in vivopharmacokinetic properties of siRNAs have,
however, prevented the realization of their full therapeutic potential [7].
The most limiting factor for the development of siRNA therapies is the
safe and efficient intracellular delivery to diseased tissues [8]. Numerous
systems have been developed with the aim of overcoming the problem
of effective siRNA delivery including liposomes [9,10], cell penetrating
peptides [11,12] and polymer nanoparticle-based systems [13]. An often
overlooked deficiency of most reported nanoparticle delivery systems
is that they cannot be adapted to different cell types in a time- and
cost-effectivemanner; crucial requirements, as it is likely that a delivery
platformmust be tailored towards its target diseased tissue types. Apart
from a few notable exceptions [14–16], detailed structure–activity
relationships for siRNA delivery platforms are absent from the
literature. This is puzzling when considering their importance in
developing and optimising a platform towards a target cell/tissue type.
Thus, there is an urgent need for a highly versatile delivery platform,
whose structural features can be rapidly and systematically modified, to
allow the determination of structure–activity relationships required for
tailoring towards a specific tissue.
We chose a cationic polymeric nanoparticle (PNP) approach for
siRNA delivery. These nanoparticles possess multiple positive charges
for electrostatic interaction with negatively charged siRNA. Therefore,
the degree of cationic charge displayed by a siRNA delivery platform is
a structural parameter of crucial importance. Adequate levels of cationic
charge are required by the PNP to ensure the complexation of siRNAved.
940 M. Omedes Pujol et al. / Journal of Controlled Release 172 (2013) 939–945cargos, promote adequate levels of PNP–cell surface interactions and
ultimately, cell transfection [17]. Unfortunately, high levels of cationic
charge have also been shown to correlate well with toxicity [15], and it
is thus vitally important that the level of cationic charge can be optimised
to ensure adequate levels of siRNA complexation and transfection with
minimal toxicity. In this manuscript we demonstrate by means of a
highly insightful three-dimensional analysis, how a simple polymer
mixed micelle [18] nanoparticle (PNP) siRNA delivery platform can be
exploited to rapidly obtain two key structure–activity relationships in
siRNA delivery: how the overall degree of cationic charge displayed by
the nanoparticles relates to i) levels of gene knockdown in vitro, and
ii) levels of cell toxicity.
2. Materials and methods
2.1. Materials, polymer synthesis, PNP preparation and characterization
Details are given in the Supplementary data.
2.2. Gene knockdown using the firefly luciferase reporter assay
Luciferase gene expression was measured using an optimised
Luciferase assay. PNP solutions were prepared at: i) different
proportions of cationic polymer (0–90% of P1), ii) different overall
polymer concentrations and iii) different siRNA (siGL3 or siAGF1)
loading concentrations.
2.2.1. 293T cells
Passaged 293T cells were seeded in 96-well plates. When the cells
reached 70–80% confluency, these were washed with PBS and fresh
DMEM D6171 with 10% FBS (150 μl) and a PNP solution (50 μl) was
added to each well.
2.2.2. SKNO cells
150μl of SKNO cells inmedia at a concentration of 0.67×106cellsml−1
was loaded in each well of 96 well plates. To each well 50 μl of a PNP
solution was added to reach a final concentration of 0.5×106cellsml−1.
The cells were incubated at 37 °C, 5% CO2, in a dark and humidified
environment for 24 h. 25 μl of 15% luciferin solution (Promega) in
media was added to each well. Luminescence was monitored with an
Omega FluoStar plate reader at a 4000 gain after 3, 5 and 10min of the
addition of the reagent. The luciferase silencing efficiencywas determined
by the relative luminescence of treated cells compared to untreated cells
(Blank).
2.3. Cell association assay (FACS)
Cell association experiments were performed using PNPs loaded with
Nile Red (NR), a hydrophobic fluorochrome that can be easily hosted in
the hydrophobic core of the micelles. Briefly, block co-polymers P1 and
P2, at the appropriate molar ratio (3.3 × 10−4 mmol polymer), were
dissolved in N,N-dimethylformamide (DMF) (0.5 ml), a solvent which
both co-polymer blocks are soluble in. Then, 200 μl of Nile Red solution
(1 mg/ml in DMF) was added, and the mixture was stirred for 5 min.
Deionised water (3.5ml) was added dropwise at a ratio of 0.04ml/min
with vigorous stirring to promote PNP formation and the NR
encapsulation. This solution was transferred into a dialysis tube MWCO
3200Da and dialysed three times against water for 24–36h. The volume
of water was adjusted to 5 ml and subsequently filtered to achieve a
polymer stock solution of 6.7 × 10−2 mM. PNPs prepared in this way
showed similar characteristics to particles prepared by sonication
(Fig. S7).
293T cells were cultured to 80–90% confluency in 12 well plates.
Prior to the transfection, cells were washed with PBS (500 μl) and
fresh media (750 μl) was added. PNP solutions with the appropriate
siRNA MR loading and polymer concentration were prepared and addedto each well (250μl). After 4hour incubation, the medium was removed
and the cells were washed twice in PBS, trypsinised and harvested with
1ml of fresh PBS for FACS analysis. In the flow cytometry measurements,
the logarithmic fluorescence intensity of untreated cells was set between
100 and 101, and all these cells with intensities higher than 101 were
considered to be positive (M1 zone), or cells that have experienced
association with the PNPs.
2.4. Cell imaging (imaging flow cytometer)
Imaging experiments using an imaging flow cytometer (Amnis
ImageStream) were performed to evaluate the cellular internalization
of these polymer nanoparticles (PNPs), their siRNA cargos and their
localisation within the cell. PNPs were prepared as described above to
encapsulate NR (NR; λex = 530 nm, λem = 615 nm); and these were
subsequently loaded with a 1:9 MR of Cy5-siAGF1/siAGF1 solution
(Cy5; λex=646nm, λem=662nm).
293T cells (50% confluent) were seeded in a 12 well plate in 1ml of
media. When the cells reached 85–90% confluency, the media was
replaced by 750 μl of fresh media, and 250 μl of 8 μM PNP50 at a 1:4
siRNA/polymer molar ratio were added to each well. After 24h each of
these samples was trypsinised and washed twice with PBS. The cells
were fixed with a 0.5% PFA solution, washed three times with PBS, and
the cell nuclei were counterstained with DAPI (2 μg/ml PBS solution) for
15min. The samples were further washed twice to remove the excess of
DAPI, re-suspended in 200 μl of PBS and analysed in the imaging flow
cytometer. The positive samples containing all three fluorochromes (NR,
Cy5 and DAPI) were used to set up each channel and the laser intensities.
Images from samples of cells containing each individual fluorochrome
(colour control) were also collected in order to facilitate compensation
between channels, allowing spectral resolution of fluorochromes with
overlapping emission spectra. Images were acquired for 1000 cells of
each sample. After selecting single and spherical cells and excluding all
these out of focus cells, a total of 211 cells were submitted to analysis.
The spot counting was achieved by using the IDEAS software, allowing
thus statistical analysis to be performed.
2.5. Cell imaging (LSCM)
Higher resolution images were obtained by using life imaging on a
Nikon A1R (invert) laser scanning confocal microscope (LSCM). 293T
cells were seeded into 35 mm diameter glass bottom petri dishes
(MatTek) and cultured to reach 50% confluency. Fresh media (1.5ml)
and a solution of PNP50 loadedwith Cy5-siAGF1 at a 1:4 siRNA/polymer
ratio that was added to a final polymer concentration of 2 μM (500 μl)
were added. After 4 h of incubation the media was replaced by fresh
one containing Hoechst 33342 nuclear staining (Invitrogen) at a
concentration of 2 μg/ml and incubated for further 15 min. The cells
were washed twice with PBS and imaged at a ×40 magnification.
2.6. Cell viability assay
Cytotoxicity was assessed using the WST-1 assay, a colorimetric
enzyme activity assay (Roche Bioscience). PNP solutions in medium
were prepared at different proportions of cationic polymer (0–90%
of P1), at different overall polymer concentrations (0.4–4 μM), and at
different siRNA (siGL3 or siAGF1) loading concentrations (50 nM,
150 nM and 800 nM) analogously to the reporter gene assays in 2.11.
Passaged 293T cells were seeded in 96-well plates. When the cells
reached 80–90% confluency, these were washed with PBS and fresh
media (75 μl) and each specific PNP solution (25 μl) was added to each
well. The cells were incubated at 37°C, 5% CO2, in a dark and humidified
environment for 24 h. 10 μl of WST-1 reagent was then added to each
well and, after 2h, the absorbancewasmeasured on anOmega FluroStar
plate reader at a λ=455nm versus 655nm.
Table 1
Listing of the eleven PNP constructs and their compositions.
Entry PNP Proportion of P1 (%) Proportion of P2 (%)
1 PNP0 0 100
2 PNP10 10 90
3 PNP20 20 80
4 PNP30 30 70
5 PNP40 40 60
6 PNP50 50 50
7 PNP60 60 40
8 PNP70 70 30
9 PNP80 80 20
10 PNP90 90 10
11 PNP100 100 0
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3.1. Polymer nanoparticle design and characterization
The PNP platform exploits the utilisation of a mixed micelle design
strategy [18] (Fig. 1), providing a remarkably rapid and versatile
approach for synthesis, with the capacity for structural adaptation. The
PNPs are prepared from the self-assembly of two different amphiphilic
diblock copolymers (P1, P2) into a stable mixed micelle which can
be considered a polymeric nanoparticle. Both P1 and P2 possess
hydrophobic blocks of similar Mw of 4.5kDa based upon biocompatible
poly(caprolactone) (PCL), but differ in their hydrophilic blocks, with P1
possessing an 15.5 kDa poly((dimethylamino)ethylene methacrylate)
(PDMAEMA) block which is partially protonated under physiological
conditions [14,19,21], and P2 possessing a 5 kDa PEG block resulting
in total molecular weights of 9.5 kDa and 20 kDa for P1 and P2. The
partially protonated amine groups in P1 will complex siRNA cargo and
possess sufficient buffering capacity to promote endosomal rupture
through the ‘proton sponge effect’ [22], facilitating endosomal escape
into the cell. The function of PEG block, if suitably long enough, is to
provide colloidal stability to the micelle, and to shield the siRNA cargo,
thus increasing its in vivo circulation times. Importantly, the net cationic
charge displayed by the PNP can be modulated simply by changing the
molar ratios of P1:P2. This mixedmicelle approach negates the need for
extensive and time-consuming resynthesis of PNPs as, unlike triblock
copolymers (ABC or ABA) [23–25], and single diblock copolymers (AB)
[26,27], the two independent amphiphilic diblock copolymers (AB and
CB) open the possibility of constructing rapidly numerous mixed micelle
compositions.
Eleven PNPs were prepared (Table 1), in which the molar ratio of P1:
P2 was changed from 100:0 to 0:100 in 10% intervals to afford PNP0–
PNP100, where the number indicates the percentage of cationic polymer
P1 chain within the mixed micelle. Dynamic light scattering (DLS)
indicated the formation of nanoparticles with hydrodynamic diameters
ranging from 30 to 80 nm, which size is in the appropriate range to
allow the exploration of enhanced permeability and retention effects
(Fig. 2A, top). Loading of this series of PNPs with siRNA in a 1:4 molar
ratio of siRNA to polymer (P1 + P2) increased the hydrodynamic
diameter by ~20%, implying a degree of PNP swelling upon siRNA
complexation. TEM analysis (Figs. 2B, S8) of PNP50 loaded with siRNA
confirmed discrete spherical nanoparticles with diameters of 40–50 nm,
which is smaller than the hydrodynamic diameters measured by DLS
(Figs. 2C, S9). The difference between sizes in DLS and TEM can be
attributed to solvation of the coronal hydrophilic polymer chains,
resulting in a larger PNP diameter in solution. Both DLS and TEM studiesFig. 1. Design of a mixed micelle delivery system, formed from self-assembly of diblock
copolymers P1 and P2. These polymers share the same hydrophobic block, polycaprolactone
(pink block), which forms the core of the micelle, but differ on their hydrophilic blocks; a
cationic PDMAEMA block in P1 (blue block), and a 5 kDa polyethylene glycol (PEG) block
in P2 (red block) forming the outer shell of the micelle. The cationic block is decorated
with amino functions, partially protonated at physiological pH,which allows the electrostatic
interactionwith thenegatively charged siRNA. PEG, a slightly longer block, provides shielding
and stability to the system. This mixed micelle delivery system is highly versatile. By simply
varying the molar ratio P1/P2, leads to a rapid optimisation of the overall cationic charge
within the particle, which aids its abilities to deliver siRNA tissue/cell specific.indicate the formation of well-defined spherical nanoparticles, and the
hydrodynamic diameter of siRNA-loaded PNPs remained stable over
a time period of 40 days, suggesting a substantial shelf-life of these
PNPs (Fig. S10).
The degree of net cationic charge present within each PNP was
estimated by ζ-potential measurements (Fig. 2A, bottom), which show
that the ζ-potential increases as the proportion of P1 increases up to
PNP30, after which it plateaus at 30mV. Interestingly, the same trend
is observed when the PNPs are loaded with siRNA. Gel retardation
experiments show that a 1:4 ratio of siRNA:polymer shows a good
level of siRNA complexation with most formulations containing ≥30%
P1 (Figs. 2D and S11). When observed in both deionized water and
saline PNP50 loaded with a 1:6 ratio of [siRNA]:[P1+P2] the size and
PDI of the PNP did not change significantly, although the ζ-potential of
the PNPs in saline was decreased (Fig. S12).
The size of particles was observed in media containing up to 20%
serum (Figs. S13–S14, Table S1). Particles appeared to swell by between
20 and 40% of their size in FBS free media and the PDI increased
drastically, although this is in part due to the detection of particles
present in the serum by DLS.
The critical micelle concentration (CMC) indicates the lowest
concentration at which micelles and PNPs can form. The CMC for
unloaded PNP50was 300nM. PNP50 loadedwith siRNA after and during
micelle assembly gave CMCs of 880 nM and 1.7 μM, respectively, which
implies a destabilisation of the micellar structure by the complexed
siRNA (Fig. 3). Importantly, these CMC values mark the lower limit of
PNP concentration which can be applied in vitro and in vivo whilst
ensuring the integrity of the micelle.3.2. Cell association and internalization
To better understand the cell association and uptake properties of
these PNPs, further experiments were performed in human 293T cells
which were analysed using flow cytometry, imaging flow cytometry
and confocal microscopy. To that end, we loaded the PNPs to saturation
with Nile Red (NR), a highly hydrophobic dye, which is encapsulated
within the PCL core of the particle and, Cy5-labelled siAGF1 for tracking
of the siRNA cargo. The incorporation of thesefluorophores into the PNP
did not significantly alter the particle size or zeta potential. Importantly,
all experiments were performed in the presence of 10–20% foetal calf
serum to mimic in vivo conditions. Flow cytometry showed that the
PNP concentration, but not the siRNA/polymer molar ratio (i.e. the N/P
ratio) or the proportion of P1 in the PNPs correlatedwith cell association
(Figs. S15–17). Confocal microscopy and imaging flow cytometry
independently showed the presence of NR-positive punctate pattern
in the cell cytoplasm within 5 h after addition of siRNA-PNP50
nanoparticles to cells, indicating cellular uptake of the nanoparticles
via an endosomal route (Figs. 4 and 5A). Importantly, the Cy5 signal
is located in the same vesicles as the NR proving co-localisation of
PNP and siRNA (Fig. 5B).
Fig. 2.A)Bar charts showinghowparticle diameter (top) and ζ-potential (bottom) change
as the proportion of P1 within the PNP increases. The PDIs of PNPs were all b0.3 B) TEM
images of PNP50 loadedwith a 1:4MR siRNA/polymer. C) A typical particle size histogram
for a PNP (PNP50) loaded with siRNA displayed by dynamic light scattering analysis
(PDI = 0.2). D) Gel electrophoresis of PNP50 loaded with different ratios of siRNA/
polymer. siRNA appears to be fully incorporated into the complex at a ratio 1:4 with
total polymer. Naked siRNA was used as a control.
Fig. 3. The critical micelle concentration (CMC) of a nanoparticle is the concentration
above which any added amphiphilic molecules have a high probability of appearing as
micellar aggregates. This factor sets a lower limit on the concentration atwhich themicelle
will be effective. Using the pyrene fluorescence spectroscopy method which utilises the
changes in the intensity of the vibrational bands of pyrene depending on the solvent
environment by measuring the changes in fluorescence at I322.5 (pyrene in a hydrophilic
environment) and I338 (pyrene in a hydrophobic environment) and plotting the I338/I322.5
the CMC of PNP50s was estimated by differentiating the point of inflection of the slope and
using this equation to calculate where the slope crosses the base line of the curve [28]. The
loading of siRNA to the PNP increases the CMC of the particle from 300 nM (circles) to
880nM (triangles)when siRNAwas added aftermicelle formulation and to 1.7μM(squares)
when added before.
Fig. 4. Confocal microscopy images of 293T cells incubated with 700 nM of Cy5-siAGF1/
siAGF1 (1:9 MR) loaded onto 2.8 μM PNP50 (bottom row) and without a nanocarrier
(top row), using a 40× magnification.
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In order to demonstrate functional cytoplasmic siRNA release we
measured the knockdown capacity of siRNA-loaded PNPs. Knockdown
experiments were performed with a reporter cell line, 293T SLIEW,
which stably expresses the gene coding for firefly luciferase. Cells were
treated with PNP50 loaded either with anti-luciferase siRNA siGL3 or a
control siRNA siAGF1 targeting the RUNX1/ETO fusion gene at a molar
siRNA to polymer ratio of 1:4. Under these conditions, we observed a
very robust (70%) and highly reproducible (p b 0.001) siGL3-specific
knockdown of luciferase activity indicating an efficient cytosolic release
of functional siRNA. Furthermore, the negative siAGF1 control showed
that this suppression of luciferase is due to RNA interference and not to
toxicity-related impairment of luminescence (Fig. 5C).
3.4. Three dimensional analysis: determination of structure–activity
relationship
Confident that the PNPs are capable of facilitating siRNA uptake and
geneknockdown, the SARsbetween cationic charge and geneknockdown
and toxicity were investigated. We applied an assay in which the level of
gene knockdown was determined as a function of three variables:
i) the cationic charge displayed by the PNP (which is modulated by
the ratio of P1:P2), ii) the overall PNP concentration, and iii) the siRNA
concentrations. This assay allows for a “three-dimensional” analysis to
determine the influence of these three variables on knockdown. To that
end we used a luciferase reporter gene in a 96 well plate format to
gauge the effect of treatment with PNP:siRNA formulations loaded withthe luciferase siRNA siGL3 on cell luminescence. siAGF1, an siRNA
targeted to RUNX1/ETO as a control. Any knockdown seen in the cells
treated with the control siRNA is on account of toxicity rather than
siRNA action (Fig. 6A), whereas knockdown observed in the cells
treated with siGL3 must arise on account of both actual knockdown
and toxicity effects (Fig. 6B). The effects of siRNA concentration were
addressed by performing the assay at three levels of siRNA loading.
The typical 3D plot obtained with 293T SLIEW cells, Fig. 6A, shows
that as the proportion of cationic polymer within the PNP increases
(x-axis), and as the overall PNP concentration increases (y-axis), the
level of gene knockdown on account of toxicity also increases (white
bars, Fig. 6A). The analysis was then repeated using siGL3 as cargo. This
plot (Fig. 6B) shows a similar trend, with luciferase activity declining as
both the proportion of cationic polymer within the PNP and the overall
PNP concentration increases. However, unlike the control, siAGF1, the
inhibition of luciferase was observed for a larger range of PNP ratios and
polymer concentrations. Normalising luminescence of siAGF1 treated
cells to those treated with siGL3 for each formulation of micelle affords
Fig. 5. A) Imaging flow cytometry (ImageStream) allowed a cell count and cell imaging to be performed at the same time. Three fluorescent probes, NR (encapsulated in the PNP's
hydrophobic core), Cy5 (complexed to the siRNA) and DAPI were observed in three different channels. B) Spot count of vesicles in the cell cytoplasm containing NR and Cy5 showing
dye co-localisation. C) Luciferase gene knockdown in 293T cells is presented for both, control siRNA (siAGF1) and luciferase specific siRNA (siGL3).
943M. Omedes Pujol et al. / Journal of Controlled Release 172 (2013) 939–945a 3-dimensional bar graph (Fig. 6C), where the height of each bar
represents the level of knockdown whilst accounting for toxicity. For
the sake of clarity, those experiments which resulted in unacceptablyFig. 6. Bar graphs showing data from titrations of the total polymer concentration, proportion o
293T cells treated with PNPs loaded with the control siAGF1. Reductions in luminescence occu
loaded with the active siGL3, where reductions in luminescence occur as a consequence of bot
actual gene knockdown, omitting toxicity effects. The formulations with the highest degree of
(knockdown of N20% using siAGF1 loaded PNPs) are shown in grey. D) PNP toxicity determinehigh levels of toxicities (b80% luminescence normalised to blank cells)
have been omitted. The emergence of a ‘front’ of several formulations
which afford similar high levels of knockdown in 293T cells (Fig. 6C)f cationic polymer P1within the PNP and siRNA load of themicelle. A) Gene knockdown in
r as a consequence of toxicity effects. B) Gene knockdown in 293T cells treated with PNPs
h gene knockdown and toxicity effects. C) Normalisation of the these two data sets shows
knockdown are represented as the tallest bars. In A) and B) formulations showing toxicity
d by WST-1 assay.
Fig. 7. Bar graphs showing data from titrations of the total polymer concentration, proportion of cationic polymer P1within the PNP and siRNA load of themicelle A) Gene knockdown in
SKNO-1 cells treatedwith PNP loadedwith the control siAGF1. Reduction in luminescence occurs as a consequence of toxicity effects. B)Gene knockdown in SKNO-1 cells treatedwith PNP
loaded with the active siGL3, where reductions in luminescence occur as a consequence of both gene knockdown and toxicity effects. The formulations with the highest degree of
knockdown are represented as the tallest bars. In A) and B) formulations showing toxicity (knockdown of N20% using siAGF1 loaded PNPs) are shown in grey. The effectiveness of the
lower concentration of siRNA in these cells can be explained by cell association D); as siRNA load increases the association of PNPs with SKNO-1 cells appears to decrease.
944 M. Omedes Pujol et al. / Journal of Controlled Release 172 (2013) 939–945shows that toxicity trails knockdown. This observation implies that the
knockdown accomplished by PNPs loading 800 nM siRNA arises on
account of siRNA activity. Lowering the siRNA concentration to 200 and
50 nM (Fig. S18) caused an inferior knockdown, and particularly at
the lowest concentration, a recession of the “knockdown front” towardsFig. 8. Knockdown of the RUNX1/ETO fusion gene. A) siAGF1 is complimentary to the
fusion gene translocation and, consequently, has no effect on RUNX1 or ETO in healthy
cells. B) Knockdown of RUNX1/ETO mRNA relative to the housekeeping gene GAPDH in
SKNO-1 cells treated with 3 μΜ PNP50/500 nM siAGF1 compared to control siGL3 and
untreated cells (Mock). ****, p b 0.0001 for n=9. Error bars indicate SEM. C) Knockdown
of RUNX1/ETO fusion protein in SKNO-1 cells treatedwith 3μΜ PNP50/500nMsiRNAwith
siGL3 serving as a non-targeting control. Values represent the relative expression for each
sample normalised to GAPDH and relative to untreated cells (mock).lower P2 content caused by increased toxicity when compared to
800nM. Therefore, a dominant feature of these analyses is that successful
formulations for 293T SLIEW cells possess 30–50% cationic polymers, and
imply that higher siRNA loadings substantially diminish non-specific
inhibition of luminescence and yield higher levels of gene knockdown.
These observations also suggest that the free cationic charges of P1 are
responsible for the toxicity of the PNP. Independent cell viability
experiments validated these findings (Fig. 6D).
3.5. Three dimensional analysis of leukaemic cells growing in suspension
These experiments were repeated in SKNO-1 SLIEW cells (Fig. 7), a
human AML cell line which expresses the RUNX1/ETO fusion gene and
which as a suspension cell line is notoriously difficult to transfect [20].
This cell line shows a similar trend to the 293T cells in terms of the
toxicity of the PNPs decreasing as higher concentrations of siRNA are
used, causing the ‘front’ of most active formulations to move towards
higher P2 content. In this leukaemic cell line, the knockdown of luciferase
is highest at 500 nM siRNA and declined at 1000 nM (Figs. 7C and S19),
contrary to the 293T cells where the level of knockdown increases with
higher siRNA loading. This difference is likely due to the uptake of the
siRNA loaded PNPs into SKNO-1 cells being more dependent on the
overall positive surface charge of the PNP, and therefore the neutralisation
of this charge with siRNA appears to limit the uptake and resultant gene
knockdown. Indeed, unlike the 293T cells, increasing the siRNA:polymer
ratio decreases association with SKNO-1 cells (Fig. 7D).
3.6. Knockdown of a leukaemic fusion gene with an optimised PNP
formulation
The utility of these 3D analyses was evaluated by post-transcriptional
knockdown of the RUNX1/ETO fusion gene with siAGF1. RUNX1/ETO is
generated by a translocation between the long arms of chromosomes 8
and 21 t(8;21) and is found in 10–15% of cases of AML [29]. siAGF1
945M. Omedes Pujol et al. / Journal of Controlled Release 172 (2013) 939–945comprises an siRNA that is specific to t(8;21) (Fig. 8A) and consequently
has no effect on cells lacking the translocation. A 3μMPNP50 loadedwith
500 nM siRNA, which exhibited good gene knockdown and was not
shown to be toxic by the 3D analysis, caused a comparable of knockdown
of RUNX1/ETO in t(8;21) positive SKNO-1 cells, both at mRNA level
(Fig. 8B), and at protein level (Fig. 8C).
4. Conclusion
These 3D plots allow a high throughput screen of PNPs which can be
used to identify the optimum drug formulation for a specific set of
conditions. This approach will be useful for the further development
and selection of formulations to take forward to in vivo studies. However,
it is also important to note the clear toxicity of the cationic diblock used in
this system, which should be considered in the future development of
formulations.
This work highlights how a versatile mixed micelle polymer
nanoparticle, in combination with the introduction of a 3-dimensional
assay, which allows the rapid construction of SARs involving cationic
charge and gene knockdown/toxicity. It permits the rapid determination
of the optimal level of cationic charge to facilitate knockdown, and the
optimal levels of PNP and siRNA loading to achieve prominent gene
knockdown in such different systems such as 293 T and SKNO-1 cells
and diminishes the expression of the “undruggable” cancer-specific
fusion gene RUNX1/ETO. These particles show promise for the future
of siRNA delivery.
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